{"id":"advanced-medical-therapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Increased risk of infections"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108889","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by enhancing the body's natural immune response to fight diseases. This is achieved through a complex interplay of immune cells and signaling pathways.","oneSentence":"Advanced Medical Therapy works by modulating the immune system to treat various conditions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:51.147Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis"},{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT04704661","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-09","conditions":"Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma","enrollment":51},{"nctId":"NCT04550494","phase":"PHASE2","title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-26","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma","enrollment":36},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT06203600","phase":"PHASE2, PHASE3","title":"Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-24","conditions":"Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":224},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT03854474","phase":"PHASE1, PHASE2","title":"Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-11-18","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8","enrollment":30},{"nctId":"NCT04090398","phase":"PHASE2","title":"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-04","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone","enrollment":70},{"nctId":"NCT06982222","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":24},{"nctId":"NCT05111561","phase":"PHASE1","title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-02","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":42},{"nctId":"NCT05136196","phase":"PHASE2","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-06","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT03191149","phase":"PHASE2","title":"Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-04-25","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7","enrollment":46},{"nctId":"NCT03375320","phase":"PHASE3","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-26","conditions":"Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm","enrollment":298},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT05058651","phase":"PHASE2, PHASE3","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-28","conditions":"Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma","enrollment":189},{"nctId":"NCT05327010","phase":"PHASE2","title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-14","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":88},{"nctId":"NCT05677100","phase":"NA","title":"Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure","status":"RECRUITING","sponsor":"Procyrion","startDate":"2023-08-23","conditions":"Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome","enrollment":320},{"nctId":"NCT05687136","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-07","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":66},{"nctId":"NCT04595747","phase":"PHASE2","title":"Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-03","conditions":"Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor","enrollment":48},{"nctId":"NCT03210714","phase":"PHASE2","title":"Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-05","conditions":"Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor","enrollment":20},{"nctId":"NCT07198074","phase":"PHASE3","title":"Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-01-27","conditions":"Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma","enrollment":255},{"nctId":"NCT04071236","phase":"PHASE1, PHASE2","title":"Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-10-14","conditions":"Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes","enrollment":90},{"nctId":"NCT05172245","phase":"PHASE1","title":"Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-09-19","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT05554380","phase":"PHASE2","title":"Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-22","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":33},{"nctId":"NCT03793166","phase":"PHASE3","title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-07","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes","enrollment":1175},{"nctId":"NCT05904080","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-19","conditions":"Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT07012031","phase":"PHASE1, PHASE2","title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-07","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":37},{"nctId":"NCT05564403","phase":"PHASE2","title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-09","conditions":"Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma","enrollment":66},{"nctId":"NCT04172532","phase":"PHASE1, PHASE2","title":"Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-11","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":92},{"nctId":"NCT04533750","phase":"PHASE1","title":"Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-20","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT07195734","phase":"PHASE2","title":"Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-09","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":180},{"nctId":"NCT04751370","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-08","conditions":"Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":31},{"nctId":"NCT04071223","phase":"PHASE2","title":"Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-29","conditions":"Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma","enrollment":134},{"nctId":"NCT06568172","phase":"PHASE3","title":"Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-18","conditions":"Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma","enrollment":420},{"nctId":"NCT04981509","phase":"PHASE2","title":"Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-10","conditions":"Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma","enrollment":65},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT05411094","phase":"PHASE1","title":"Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-22","conditions":"Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":18},{"nctId":"NCT04394858","phase":"PHASE2","title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma","enrollment":46},{"nctId":"NCT06606990","phase":"PHASE1","title":"Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-07-01","conditions":"Metastatic Malignant Solid Neoplasm","enrollment":40},{"nctId":"NCT03213652","phase":"PHASE2","title":"Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-04-17","conditions":"Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma","enrollment":13},{"nctId":"NCT03244384","phase":"PHASE3","title":"Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-03","conditions":"Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":739},{"nctId":"NCT07042295","phase":"PHASE2","title":"Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-23","conditions":"Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma","enrollment":86},{"nctId":"NCT04929041","phase":"PHASE2, PHASE3","title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-07","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma","enrollment":427},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT02453620","phase":"PHASE1","title":"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-02-12","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma","enrollment":57},{"nctId":"NCT03914300","phase":"PHASE2","title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-02-10","conditions":"Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma","enrollment":11},{"nctId":"NCT06900595","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-02-22","conditions":"Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma","enrollment":48},{"nctId":"NCT06311214","phase":"PHASE2","title":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-18","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":500},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT06096844","phase":"PHASE3","title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-19","conditions":"Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8","enrollment":304},{"nctId":"NCT05638295","phase":"PHASE2","title":"Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":105},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT05510908","phase":"","title":"Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2023-07-25","conditions":"HIV-Associated Malignant Neoplasm, HIV Infections, Cancer","enrollment":460},{"nctId":"NCT04216316","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-14","conditions":"Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":12},{"nctId":"NCT05929664","phase":"PHASE2","title":"Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-07-05","conditions":"Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma","enrollment":70},{"nctId":"NCT04128995","phase":"PHASE4","title":"Surgical or Medical Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-12-15","conditions":"Diabetes Mellitus, Type 2, Pediatric Obesity, Bariatric Surgery Candidate","enrollment":88},{"nctId":"NCT04514484","phase":"PHASE1","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-22","conditions":"Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma","enrollment":8},{"nctId":"NCT07089940","phase":"EARLY_PHASE1","title":"OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2026-01-27","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":12},{"nctId":"NCT02503423","phase":"PHASE1, PHASE2","title":"Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2015-07-14","conditions":"Solid Tumors, Lymphoma","enrollment":253},{"nctId":"NCT06054854","phase":"","title":"Biobank for the Identification of Biomarkers in Lung Cancer (BIRD, Biomarkers in Respiratory Disease)","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2024-06-13","conditions":"Lung Nodule, Lung Cancer","enrollment":3000},{"nctId":"NCT06911008","phase":"PHASE1","title":"MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-11-07","conditions":"Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":42},{"nctId":"NCT04016142","phase":"PHASE2","title":"Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2020-07-15","conditions":"Locally Advanced Cancer, Cervical Cancer","enrollment":21},{"nctId":"NCT06412510","phase":"PHASE1, PHASE2","title":"Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-09-05","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Pancreatic Adenocarcinoma","enrollment":22},{"nctId":"NCT05422794","phase":"PHASE1","title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-18","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma","enrollment":57},{"nctId":"NCT07475949","phase":"PHASE3","title":"Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-04","conditions":"Acute Ischemic Stroke, Tenecteplase","enrollment":352},{"nctId":"NCT07474441","phase":"","title":"Early Coronary Angiography in Advanced Chronic Kidney Disease With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2017-01-01","conditions":"CKD, ACS (Acute Coronary Syndrome), Coronary Angiography (CAG)","enrollment":139},{"nctId":"NCT06221397","phase":"","title":"AI-based Medical Device Validation for Early Melanoma Detection","status":"COMPLETED","sponsor":"AI Labs Group S.L","startDate":"2020-09-17","conditions":"Melanoma, Melanoma, Skin","enrollment":105},{"nctId":"NCT07322341","phase":"PHASE2","title":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-06-01","conditions":"Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma","enrollment":32},{"nctId":"NCT03808675","phase":"NA","title":"Aerobic Exercise in Parkinson's Disease","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-07-01","conditions":"Parkinson's Disease","enrollment":57},{"nctId":"NCT05269381","phase":"PHASE1, PHASE2","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-03-31","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8","enrollment":132},{"nctId":"NCT06909682","phase":"","title":"AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices","status":"RECRUITING","sponsor":"University of Salerno","startDate":"2025-08-01","conditions":"Chronic Heart Failure, Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction (HFrEF)","enrollment":205},{"nctId":"NCT06580054","phase":"PHASE2","title":"Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-03-05","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","enrollment":22},{"nctId":"NCT07017829","phase":"PHASE2","title":"GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":"Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":28},{"nctId":"NCT05010109","phase":"NA","title":"Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-05","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":100},{"nctId":"NCT07443098","phase":"NA","title":"Front Line Agreement in Diagnosis and Treatment for Musculoskeletal Dysfunctions","status":"COMPLETED","sponsor":"Bern University of Applied Sciences","startDate":"2023-10-03","conditions":"Musculoskeletal Diseases, Low Back Pain, Emergency Service, Hospital","enrollment":102},{"nctId":"NCT05396872","phase":"NA","title":"Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-05-12","conditions":"Prostate Cancer, Advanced Prostate Carcinoma","enrollment":250},{"nctId":"NCT03941730","phase":"PHASE2","title":"Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-08-28","conditions":"Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":8},{"nctId":"NCT06745076","phase":"PHASE2","title":"Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-03-06","conditions":"Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8","enrollment":125},{"nctId":"NCT06082804","phase":"NA","title":"Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"Centre Hospitalier Henri Duffaut - Avignon","startDate":"2023-11-29","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":60},{"nctId":"NCT04771806","phase":"","title":"Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-01","conditions":"Malignant Glioma","enrollment":80},{"nctId":"NCT05050162","phase":"PHASE2, PHASE3","title":"Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer","status":"SUSPENDED","sponsor":"NRG Oncology","startDate":"2022-02-01","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma","enrollment":1714},{"nctId":"NCT06434064","phase":"PHASE2","title":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-15","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma","enrollment":30},{"nctId":"NCT04701437","phase":"NA","title":"Advanced Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2021-12-17","conditions":"Hepatitis C","enrollment":80},{"nctId":"NCT05863351","phase":"PHASE3","title":"Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-09-07","conditions":"Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8","enrollment":472},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT07437053","phase":"EARLY_PHASE1","title":"Sarcopenia in Chronic Kidney Disease (CKD) Patients","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-06-01","conditions":"Chronic Kidney Disease, Sarcopenia","enrollment":20},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT06616623","phase":"PHASE1","title":"Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Dwight Owen","startDate":"2024-12-31","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":24},{"nctId":"NCT04294628","phase":"PHASE1","title":"Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-01","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":62},{"nctId":"NCT06178588","phase":"PHASE2","title":"Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2024-02-01","conditions":"Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Recurrent Cholangiocarcinoma","enrollment":15},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT06572735","phase":"","title":"Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-09-24","conditions":"Ovarian Cancer","enrollment":50},{"nctId":"NCT04526730","phase":"PHASE2","title":"Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-12-22","conditions":"Melanoma","enrollment":17},{"nctId":"NCT06051695","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","status":"RECRUITING","sponsor":"A2 Biotherapeutics Inc.","startDate":"2024-04-03","conditions":"Solid Tumor, Adult, Colorectal Cancer, NSCLC","enrollment":474},{"nctId":"NCT06550310","phase":"","title":"Nutrition and Clinical Outcomes in IBD","status":"RECRUITING","sponsor":"Barts & The London NHS Trust","startDate":"2024-10-24","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":300},{"nctId":"NCT03212274","phase":"PHASE2","title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-30","conditions":"Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma","enrollment":89},{"nctId":"NCT07155850","phase":"NA","title":"Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC","status":"RECRUITING","sponsor":"BetaGlue Therapeutics SpA","startDate":"2026-02-03","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced, Unresectable","enrollment":10},{"nctId":"NCT03317392","phase":"PHASE1, PHASE2","title":"Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-04","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":145},{"nctId":"NCT07419945","phase":"NA","title":"Older Kidney Patient Optimisation Pretransplant","status":"NOT_YET_RECRUITING","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2026-02-02","conditions":"Kidney Disease, Kidney Failure, Frailty","enrollment":50},{"nctId":"NCT06006013","phase":"PHASE2","title":"Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-15","conditions":"Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma, Stage III Adrenal Cortex Carcinoma","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Advanced Medical Therapy","genericName":"Advanced Medical Therapy","companyName":"Hadassah Medical Organization","companyId":"hadassah-medical-organization","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Advanced Medical Therapy works by modulating the immune system to treat various conditions. Used for Multiple sclerosis, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}